Details

---

Manufacturer
SANDOZ GMBH
 
Contents
Octreotide acetate
 
Indication
Acromegaly, Variceal haemorrhage in patients with cirrhosis, Prophylaxis of complications following pancreatic surgery, Secretory neoplasms, HIV-associated diarrhoea
 
Instruction
Administer via SC and IV Infusion
 
Drug interaction
Dosage adjustment of concurrent therapy may be necessary with calcium channel blockers, oral hypoglycaemics, β-blockers, diuretics. May increase concentration of bromocriptine.
Potentially Fatal: Requirements of insulin may be reduced requiring careful blood-glucose monitoring. Reduction in ciclosporin bioavailability and efficacy.